News

Parkinson’s patients treated with deep brain stimulation (DBS) are not more impulsive than other patients or healthy people toward food or monetary rewards, according to new research. The study, “Deep brain stimulation of the subthalamic nucleus and the temporal discounting of primary and secondary rewards,” was…

AbbVie and Voyager Therapeutics have extended their collaboration to co-develop and commercialize antibodies that target the toxic forms of alpha-synuclein to treat Parkinson’s disease and other synucleinopathies. The collaboration will combine AbbVie’s expertise in monoclonal antibodies with Voyager’s gene therapy platform to deliver antibodies across the blood-brain barrier…

A palm-worn device can quantify joint stiffness in Parkinson’s disease patients by tracking changes in rigidity following treatment with deep brain stimulation, and may be of use in measuring fluctuations in motor symptoms, scientists who created the tool report. Their study, “A Palm-Worn Device to Quantify Rigidity in…